Fatty acids for controlling ketosis

By using a composition of butyric acid or acetic acid and adding propionic acid when the blood ketone level is higher than 3mmol/L, the problem of instability of blood ketone levels is solved, and the continuous control of ketosis status and patient compliance is achieved. Improvement.

CN119072305APending Publication Date: 2024-12-03NV NUTRICIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036012.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-02
Filing Date
2023-03-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing compositions have instability in maintaining blood ketone levels, resulting in temporary high or low levels, affecting efficacy and increasing side effects, low patient compliance, and a replacement composition with sustained release or controlled release doses is needed to maintain Treated effective blood ketone concentration.

Method used

Using a composition of butyric acid or acetic acid and adding propionic acid when blood ketone levels are above 3 mmol/L, provides a strategy for controlling and regulating blood ketone levels by dose-dependent reduction of ketone production.

Benefits of technology

Effectively maintain therapeutic ketosis status, improve patient compliance and tolerance, reduce side effects, and ensure that blood ketone levels are within the effective range of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005099499350000271
    Figure BDA0005099499350000271
  • Figure BDA0005099499350000281
    Figure BDA0005099499350000281
  • Figure HDA0005099499360000011
    Figure HDA0005099499360000011
Patent Text Reader

Abstract

The present invention relates to providing a first composition of at least one of acetic acid or butyric acid to control ketosis associated with a ketogenic diet in a subject following the ketogenic diet wherein controlling ketosis involves a) administration of the first composition, b) optionally, administration of a second composition comprising propionic acid to reduce ketogenic production / , with blood ketogenic levels higher than (3) mmol / L, administration of at least one of acetic acid and butyric acid to control ketosis associated with the ketogenic diet in a subject following the ketogenic diet. A second composition comprising propionic acid is applied.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to controlling or regulating the level of ketone bodies in the blood using the first or second composition and to a combination of the first and second composition for use for this purpose. Background Art

[0002] Ketosis is a state of elevated blood ketone levels due to a ketogenic diet, caloric restriction, (therapeutic) fasting, and / or supplementation with ketogenic precursors. Ketone bodies are energy substrates for both peripheral tissues and the central nervous system. The two most abundant and physiologically significant ketone bodies are acetoacetate and β-hydroxybutyrate, while the third ketone body, acetone, is exhaled from the lungs as a byproduct.

[0003] The metabolism of ketone bodies has been implicated in therapeutic effects in a variety of therapeutic areas, including neurological disorders (e.g., epilepsy and aging-related conditions such as Alzheimer's disease), neuromuscular diseases (e.g., amyotrophic lateral sclerosis, stroke, and neurotrauma), metabolic disorders (e.g., obesity, insulin resistance, type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases).

[0004] Although the ketogenic diet can effectively increase blood ketone levels and has a wide range of therapeutic applications, the patient's compliance is low due to the dietary restrictions of this diet therapy. In addition to the ketogenic diet, exogenous ketone bodies (such as exogenous β-hydroxybutyrate) can also be used to establish or maintain nutritional ketosis. However, the current composition and / or its dosage form can cause blood ketone concentrations to change over time, resulting in temporary unnecessary high levels or ineffective levels and / or lack of satisfactory sensory properties. This not only reduces the efficacy of ketone bodies, but may also aggravate adverse side effects such as gastrointestinal discomfort (Clarke et al., Regul Toxicol Pharmacol. [Regulatory Toxicology and Pharmacology] August 2012; 63 (3): 401-8; WO 2018115158A1), which in turn leads to reduced patient compliance and / or limits its wider use. Therefore, there is still a need for alternative compositions to maintain effective and well-tolerated blood ketone body concentrations.

[0005] Therefore, there is a need for a composition that can be used to support sustained or controlled release dosage to a subject. In particular, such a composition should be able to maintain blood ketone body concentration at a therapeutically effective level, preferably with good tolerability and organoleptic properties. The above technical problem can be solved by the embodiments defined in the claims. Summary of the invention

[0006] The inventors have observed that after administration of a first composition providing at least one of butyrate or caproate and optionally acetic acid, the level of ketone bodies produced by a ketogenic diet increases, and after administration of a second composition comprising propionic acid, the ketone body production decreases. The inventors have found that using the first and second compositions, a strategy for controlling and / or regulating blood ketone levels to achieve or maintain a therapeutic ketosis state is provided. The inventors have found that the second composition comprising propionic acid is able to reduce ketone production in a dose-dependent manner.

[0007] The inventors have found that a first composition providing at least one of butyrate or caproate and optionally acetic acid is beneficial for the following therapeutic use: (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet, wherein the first composition providing at least one of butyrate or caproate and optionally acetic acid is a composition comprising a non-ketogenic amount of at least one of butyrate or caproate and optionally acetic acid or a composition comprising a dietary fiber blend providing a non-ketogenic amount of at least one of butyrate or caproate and optionally acetic acid, wherein the therapeutic use involves a) administering the first composition, c) optionally, administering a second composition comprising propionic acid, provided that the blood ketone level is above 3 mmol / L. Preferably, the therapeutic use involves b) measuring blood ketone and / or urine ketone levels.

[0008] Furthermore, the present invention relates to propionic acid for therapeutic use in i) controlling the effects of a ketogenic diet and / or ii) controlling ketone body production in a subject following a ketogenic diet and using a first composition providing at least one of butyrate or caproate and optionally further acetic acid.

[0009] In other words, the present invention relates to the use of a first composition providing at least one of butyric acid or caproic acid and optionally acetic acid and a second composition comprising propionic acid in the manufacture of a product for (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet.

[0010] Furthermore, the present invention relates to a (non-therapeutic) method for (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet, the method comprising administering to the subject an effective amount of a first composition providing at least one of butyrate or caproate and optionally acetic acid and / or a second composition comprising propionic acid.

[0011] The present invention further provides a kit comprising: 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1; 2) a first composition providing at least one of butyrate or caproate and optionally acetic acid; 3) a second composition comprising propionic acid.

[0012] Also provided is a kit for use in: (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following a ketogenic diet, the kit comprising

[0013] 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1;

[0014] 2) providing a first composition of at least one of butyric acid or hexanoic acid and optionally acetic acid;

[0015] 3) A second composition comprising propionic acid.

[0016] Figure List

[0017] The present invention will be discussed in more detail below with reference to the accompanying drawings.

[0018] Figure 1: Effects of C2 fatty acids on hepatocyte ketone production.

[0019] Figure 2: Effects of C4 fatty acids on ketone production in hepatocytes.

[0020] Figure 3: Effects of C6 fatty acids on ketone production in hepatocytes.

[0021] Figure 4: Effects of citrate on hepatocyte ketone production.

[0022] Figure 5: Effect of nicotinamide riboside on cellular NAD content.

[0023] Figure 6: Effects of nicotinamide riboside on ketone production in hepatocytes.

[0024] Figure 7: Effects of C3 fatty acids on ketone production in hepatocytes.

[0025] Figure 8: Effects of increasing doses of C3 fatty acids on cell viability

[0026] Figure 9: Effects of combinations of C4 and C6 fatty acids on hepatocyte ketone production.

[0027] Fig.10 : Effects of combinations of C4, C6, citrate, and NR or NAM on hepatocyte ketone production.

[0028] Fig.11 : Weight ratio of butyrate to propionate from 24-h fermentation of dietary fiber.

[0029] List of Examples

[0030] 1. A first composition providing at least one of butyric acid or caproic acid and optionally acetic acid, the composition being used for

[0031] Controlling ketosis associated with the ketogenic diet in subjects following the ketogenic diet,

[0032] wherein at least one of the butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition,

[0033] The therapeutic use involves

[0034] a) administering the first composition to the subject,

[0035] c) Optionally, administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid if the blood ketone level is above 3 mmol / L.

[0036] 2. The first composition for use according to embodiment 1, wherein the therapeutic use further involves b) measuring blood ketone and / or urine ketone levels.

[0037] 3. A first composition for use according to embodiments 1 and 2, wherein the first and second compositions are used sequentially, optionally more than once in sequence.

[0038] 4. The first composition for use according to any one of the preceding embodiments, wherein the subject following the ketogenic diet suffers from a condition selected from the group consisting of:

[0039] i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine;

[0040] ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI);

[0041] iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age;

[0042] iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder;

[0043] v) metabolic disorders, including insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases;

[0044] vi) tumor diseases;

[0045] vii) Cardiovascular disease leading to heart failure.

[0046] 5. The first composition for use according to any one of the preceding embodiments, wherein the first composition further comprises one or more compounds selected from citrate, nicotinamide riboside, and nicotinamide.

[0047] 6. A first composition for use according to any one of the preceding embodiments, wherein the first composition comprises

[0048] (i) Butyric acid

[0049] (ii) Hexanoic acid

[0050] (iii) Citrate and

[0051] (iv) Nicotinamide riboside or nicotinamide.

[0052] 7. The first composition for use according to any one of the preceding claims, wherein the first composition is administered at the following dosage:

[0053] (i) 0.2 to 12 mg butyrate per kg body weight per day

[0054] (ii) 6 to 165 mg of caproic acid per kg body weight per day

[0055] (iii) 0.01 g to 0.4 g citrate per kg body weight per day, and

[0056] (iv) 0.5 mg to 15 mg of nicotinamide riboside per kg body weight per day.

[0057] 8. The first composition for use according to any one of the preceding embodiments, wherein the first composition enhances ketosis in a subject following a ketogenic diet.

[0058] 9. The first composition for use according to any one of the preceding embodiments, wherein the second composition (i) reduces ketone production and / or

[0059] (ii) prevention and / or treatment of ketoacidosis,

[0060] Wherein (i) reducing ketone production and / or (ii) preventing and / or treating ketoacidosis comprises reducing blood ketone levels to below 3 mM.

[0061] 10. Propionic acid for use in the treatment of: in a subject following a ketogenic diet and using a first composition providing at least one of butyrate or caproate and optionally acetic acid

[0062] i) Control the effects of a ketogenic diet and / or

[0063] ii) Control of ketone body production

[0064] , wherein at least one of the butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition.

[0065] 11. The propionic acid for therapeutic use according to embodiment 10, wherein i) controlling the effect of a ketogenic diet and / or ii) controlling ketone body production involves lowering blood ketone bodies to a range of 1.0 to 3.0 mmol / L.

[0066] 12. Propionic acid for therapeutic use according to embodiments 10 and 11, wherein the therapeutic use relates to

[0067] a) applying the first composition,

[0068] b) administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid.

[0069] 13. Propionic acid for therapeutic use according to embodiment 12, wherein the therapeutic use further involves c) measuring blood ketone and / or urine ketone levels.

[0070] 14. A set box, the set box comprising:

[0071] 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1;

[0072] 2) providing a first composition of at least one of butyric acid or caproic acid and optionally acetic acid, wherein the at least one of butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the at least one of butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition;

[0073] 3) A second composition comprising propionic acid.

[0074] 15. A kit for use in: (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following a ketogenic diet, the kit comprising:

[0075] 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1;

[0076] 2) providing a first composition of at least one of butyric acid or caproic acid and optionally acetic acid, wherein the at least one of butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the at least one of butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition;

[0077] 3) A second composition comprising propionic acid. DETAILED DESCRIPTION

[0078] The inventors have observed that after administration of a first composition providing at least one of butyrate or caproate and optionally acetic acid, the level of ketone bodies produced by a ketogenic diet is increased, and after administration of a second composition comprising propionic acid, the ketone body production is reduced. The inventors have discovered that using the first and second compositions provides a strategy for controlling and / or regulating blood ketone levels to achieve or maintain a state of ketosis.

[0079] The inventors have found that butyrate, caproate, and optionally acetate, when used and in amounts that produce subphysiological to physiological plasma levels, can increase or enhance ketone production in a ketogenic diet, but are not themselves metabolic substrates or precursors for ketone body production. It has also been observed that butyrate and caproate, and optionally one or more of acetate, citrate and / or nicotinamide riboside and / or nicotinamide, have a synergistic enhancing effect on ketosis.

[0080] The inventors have found that the second composition comprising propionic acid reduces ketone production in a dose-dependent manner. It has also been found that the second composition comprising propionic acid is capable of further reducing plasma ketone levels to a concentration below 3 mM and is capable of treating and / or preventing conditions where the blood pH is below 7.4. The inventors of the present invention have now observed that propionic acid is capable of reducing ketone synthesis at low physiological concentrations of 1 μM to 10 μM. Without being bound by theory, it is assumed that the use of propionate reduces fatty acid oxidation through one of the following two mechanisms: one is through a mechanism comparable to malonyl-CoA (which is an inhibitor of carnitine palmitoyltransferase 1, a protein that mediates the uptake of long-chain fatty acids into mitochondria); the other is through the conversion of methylmalonyl-CoA derived from propionate into malonyl-CoA through an unknown mechanism.

[0081] Therefore, the inventors have found that a first composition providing at least one of butyrate or caproate and optionally acetic acid is beneficial for the following therapeutic use: (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet, wherein the first composition providing at least one of acetic acid or butyrate is a composition comprising a non-ketogenic amount of at least one of butyrate or caproate and optionally acetic acid or a composition comprising a dietary fiber blend providing a non-ketogenic amount of at least one of butyrate or caproate and optionally acetic acid, wherein the therapeutic use involves a) administering the first composition, c) optionally, administering a second composition comprising propionic acid, provided that the blood ketone level is above 3 mmol / L.

[0082] Furthermore, the present invention relates to propionic acid for therapeutic use in i) controlling the effects of a ketogenic diet and / or ii) controlling ketone body production in a subject following a ketogenic diet and using a first composition providing at least one of butyrate or caproate and optionally acetic acid.

[0083] In other words, the present invention relates to the use of a first composition providing at least one of butyric acid or caproic acid and optionally acetic acid and a second composition comprising propionic acid in the manufacture of a product for (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet.

[0084] Furthermore, the present invention relates to a method for (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet, the method comprising administering to the subject a therapeutically effective amount of a first composition providing at least one of butyrate or caproate and optionally acetic acid and / or a second composition comprising propionic acid.

[0085] The present invention further provides a kit comprising: 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1; 2) a first composition providing at least one of butyrate or caproate and optionally acetic acid; 3) a second composition comprising propionic acid.

[0086] Also provided is a kit for use in: (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following a ketogenic diet, the kit comprising

[0087] 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1;

[0088] 2) providing a first composition of at least one of butyric acid or hexanoic acid and optionally acetic acid;

[0089] 3) A second composition comprising propionic acid.

[0090] definition

[0091] Throughout this application, the following terms and abbreviations may be used.

[0092] The classic ketogenic diet contains a certain amount of lipids (by weight), which may be up to about 4 times the total weight of protein and digestible carbohydrates. In the context of the present invention, the so-called ketogenic (weight) ratio is the weight ratio of the amount of lipids in the composition to the combined weight of protein and digestible carbohydrates. The ketogenic diet mentioned in the context of the present invention is a dietary intervention, which can be any type of ketogenic diet known in the art, preferably characterized by a ketogenic weight ratio between 1: 1 and 4: 1, that is, the ratio of the amount of fat to the combined amount of protein and digestible carbohydrates. Within the (sub) range of the above-mentioned ketogenic ratio of the present invention, the ketogenic diet used in the context of the present invention preferably contains a lipid weight content that is at least twice the carbohydrate weight content. The ketogenic dietary composition as used in the context of the present invention, when followed, can induce a state of ketosis.

[0093] As used herein, the term "ketosis" preferably refers to a subject's blood ketone level above 0.5mmol / L. Ketone levels maintained above 0.5mmol / L and ideally in the range of 1 to 3mmol / L appear to have a therapeutic effect in humans [Anderson JC et al., Obes Sci Pract. [Obes Science and Practice] 2021; 7(5): 646-656]. Therefore, subjects receiving the composition of the present invention preferably exhibit ketone levels within the above range. Blood ketone levels above 10mmol / L are associated with signs of ketoacidosis. Although ketosis refers to a state of elevated ketones, ketoacidosis is a pathological and potentially life-threatening condition, particularly resulting in a decrease in blood pH to below 7.4 and possibly inducing coma. Methods for detecting blood ketone and / or urine ketone levels and / or blood pH are known in the art, including test strips, portable blood ketone analyzers, enzymatic tests, and the like.

[0094] In the context of the present invention, the subject following or adopting a ketogenic diet is a mammal, preferably a human.

[0095] Fiber is an indigestible carbohydrate. Indigestible carbohydrates are carbohydrates that cannot be digested and absorbed in the human stomach and small intestine and enter the colon intact. Therefore, compounds like lactose, maltose, glucose, standard maltodextrin and standard starch are considered digestible. Fiber may or may not be fermented in the colon. The term "fermentable" refers to the ability to be broken down by microorganisms (anaerobic) into smaller molecules, particularly short-chain fatty acids and lactate, in the lower gastrointestinal tract (e.g., colon). Fermentability can be determined by the method described in Am.J.Clin.Nutr. [American Journal of Clinical Nutrition] 53, 1418-1424 (1991).

[0096] Butyrate dietary fiber is a fermentable dietary fiber. Butyrate dietary fiber or blends produce more caproate and butyrate than propionate and valerate SCFA. For the purpose of this specification, butyrate dietary fiber used in the present invention is defined as a dietary fiber or dietary fiber blend that is proven to produce butyrate and propionate in a beneficial ratio. The valeric acid and caproic acid produced by butyrate dietary fiber during fermentation are negligible.

[0097] As used herein, the terms "control" and "regulate" refer to the effect of the first and second compositions according to the present invention on maintaining a subject in a therapeutic ketosis state, wherein blood ketone body levels are ideally in the range of 1.0 to 3.0 mmol / L.

[0098] The first composition is a composition or a combination of compounds that does not increase or enhance ketone production by itself (i.e., a non-ketogenic composition), but can improve and / or enhance (enhance) the amount of ketone production induced by a ketogenic diet. Therefore, the first composition is capable of increasing ("enhancing") the amount of ketone production in a subject on a ketogenic diet, and can maintain ketosis, and preferably is also capable of increasing the rate of ketone production, while not acting as or becoming a substrate for the production of ketone bodies in the amount provided. In a subject who ingests a ketogenic diet or a ketogenic substrate, the first composition is capable of increasing ketone body production relative to the ketone body production of a subject who ingests the same amount of a ketogenic diet or a ketogenic substrate but without the first composition.

[0099] Thus, the first composition itself is not a metabolic substrate for ketone body production (i.e., the composition is non-ketogenic), but is capable of increasing or improving ketone body production of a ketogenic composition or a ketogenic diet. Optionally, a certain compound in the first composition may sometimes produce a small amount of ketone bodies that do not themselves increase plasma ketone concentrations and / or cannot cause ketosis at the dose provided, but are capable of stimulating ketone body formation of the ketogenic composition in a non-additive manner. The first composition does not have a ketogenic ratio between 1:1 and 4:1. The first composition can be incorporated into a ketogenic diet or can be a separate composition.

[0100] Conversely, ketone body levels can be equalized and reduced to blood ketone body levels within the desired therapeutic ketosis range by the second composition, which can dose-dependently reduce ketone production, thereby preventing and / or treating excessive ketone body levels and / or ketoacidosis. The first and second compositions are used simultaneously or sequentially to control or regulate blood ketone body levels. When the amounts of the first and second compositions are provided per kilogram of body weight, the body weight refers to the body weight of a subject following / adopting a ketogenic diet.

[0101] The expression "increases ketone body production" means that the amount of systemic and / or blood ketone bodies is higher in an individual who is on i) a ketogenic diet and ingests (co-administered) ii) a first composition according to the present invention, compared to an individual who is on a ketogenic diet of a similar amount and type but without the first composition. In one aspect, the first composition can reduce the time required to reach a therapeutically effective ketone concentration.

[0102] The term "reducing ketone body production" means that the amount of systemic and / or blood ketone bodies is reduced in an individual following a ketogenic diet and ingesting a second composition according to the invention, compared to an individual consuming a similar amount and type of ketogenic diet. In one aspect, the second composition is neither a metabolic substrate for the formation of ketone bodies nor a substrate in glucose metabolism.

[0103] As used herein, the expression "non-ketogenic composition" refers to a composition that, when administered, does not itself lead to ketone body formation or that itself cannot increase the amount of systemic and / or blood ketone bodies, i.e., it is not a metabolic substrate for the formation of ketone bodies, and / or it may optionally lead to the production of a small amount of ketone bodies (these ketone bodies themselves cannot lead to ketosis), but it can stimulate ketone body formation in a non-additive manner in the presence of a ketogenic diet. Therefore, as used herein, a non-ketogenic amount refers to the amount of a certain compound, wherein this compound itself does not serve as a substrate for the formation of ketone bodies or only produces very small amounts of ketone bodies. Accordingly, in response thereto, the amount of systemic and / or blood ketone bodies will not increase.

[0104] In contrast, a ketogenic composition is a composition useful for promoting ketone body formation and ketosis in a subject, wherein the composition comprises ketone bodies and / or substrates for forming ketone bodies. A ketogenic diet is an exemplary ketogenic composition.

[0105] The terms acetic acid or its derivatives, propionic acid or its derivatives, butyric acid or its derivatives and caproic acid or its derivatives encompass any compound that is converted into acetic acid or an acetate anion, propionic acid or a propionate anion, butyric acid or a butyrate anion and caproic acid or a caproate anion, respectively, in the animal body. Derivatives include food-approved esters, complexes or salts of fatty acids. Derivatives of fatty acids according to the invention include (parts of) glycerol, physiologically acceptable complexes or salts thereof (e.g. calcium, potassium, sodium, magnesium, ammonium salts) and food-approved esters.

[0106] Glycerides are esters formed by glycerol and carboxylic acids, usually in the form of fatty acids. As an example, triglycerides (also known as triacylglycerols) are triesters derived from glycerol and three carboxylic acids. Under hydrolysis conditions (such as those in the digestion process), triglycerides can be used as a source of carboxylic acids or fatty acids. For example, each mole of tributyrin may be a source of three moles of butyric acid. Some glycerides are esters formed by glycerol and fatty acids, in which not all hydroxyl groups are esterified; monobutyric acid glyceride and dibutyric acid glyceride are also sources of butyric acid according to the present invention, providing one mole and two moles of butyric acid per mole, respectively.

[0107] In the context of the present invention, when referring to the amounts of acetic acid, propionic acid, butyric acid or caproic acid, respectively, these amounts are calculated as their corresponding (molar) amounts if different sources or derivatives are used.

[0108] The term "supplement" or "dietary supplement" refers to a nutritional product that provides an individual with nutrients that the individual may not otherwise be able to conveniently consume in sufficient quantities and can be used to supplement the individual's nutrition. It can be in the form of tablets, capsules, lozenges, or liquids. Supplements typically provide selected nutrients but do not represent a major part of the subject's overall nutritional needs. Typically, they do not exceed 0.1%, 1%, 5%, 10% of the subject's daily energy needs.

[0109] In this document and its claims, the verb "comprise" and its conjugations are used in their non-restrictive sense, meaning that the part following the word is included, but parts not specifically mentioned are not excluded. In addition, referring to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one element is present, unless the context clearly requires the presence of one and only one element. "Essentially consisting of..." means that the first and second compositions contain their active ingredients and possible additional compounds, provided that these additional compounds have no substantial effect on the basic characteristics of the composition. Therefore, the indefinite article "a" or "an" usually means "at least one". When % is mentioned in this article, wt% is meant, unless otherwise specified.

[0110] Therapeutic ketosis

[0111] One aspect of the invention is a first composition comprising a therapeutically effective amount of at least one of butyrate or caproate and optionally acetic acid for use in the following therapeutic uses: (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet,

[0112] The therapeutic use involves,

[0113] 1) applying the first composition;

[0114] 2) administering a second composition comprising a therapeutically effective amount of propionic acid when the blood ketone level increases by more than 3 mmol / L,

[0115] Wherein the first composition and the second composition are administered in an effective amount for controlling or regulating ketosis in a subject on a ketogenic diet, thereby treating or preventing or ameliorating the symptoms of at least one condition selected from the group consisting of:

[0116] i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine;

[0117] ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI);

[0118] iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age;

[0119] iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder;

[0120] v) metabolic diseases, including overweight and obesity (i.e., subjects with a BMI above 25 or 30, respectively), insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage disease, and mitochondrial disease;

[0121] vi) tumor diseases;

[0122] vii) Cardiovascular disease leading to heart failure.

[0123] In a preferred aspect, the level of ketones in plasma or urine is measured by methods known in the art, such as test strips and enzymatic methods, 1) after administration of the first composition and 2) after administration of the second composition.

[0124] In one aspect of the invention, the first composition can also reduce the time required to reach a therapeutically effective ketone concentration. Reducing the time required to reach a state of ketosis is particularly useful for refractory status epilepticus. In another aspect of the invention, the first composition can also reduce the amount of fat in the ketogenic diet required to reach and / or maintain a state of ketosis. In one embodiment, the amount of fat in the ketogenic diet can be reduced by about 10% while keeping the total amount of calories in the ketogenic diet unchanged. By reducing the amount of fat in the ketogenic diet, the ketone ratio will also be reduced by about 10%. It is believed that reducing the amount of fat in the ketogenic diet can make the diet easier to follow, thereby improving patient compliance. The second composition can control and / or regulate blood ketone levels so that blood ketone levels do not become too high, especially not higher than 3mmol / L.

[0125] A further aspect of the invention is a second composition comprising a therapeutically effective amount of propionic acid for use in the following therapeutic use: (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet and using a first composition providing at least one of butyrate or caproate and optionally acetic acid, wherein the therapeutic use involves reducing and / or controlling blood ketone body levels within the range of 1 to 3 mmol / L, and wherein the first and second compositions are administered in an amount effective to control or regulate said blood ketone levels in a subject on a ketogenic diet, to treat or prevent or ameliorate the symptoms of at least one condition selected from the group consisting of:

[0126] i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine;

[0127] ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI);

[0128] iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age;

[0129] iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder;

[0130] v) metabolic diseases, including overweight and obesity (i.e., subjects with a BMI above 25 or 30, respectively), insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage disease, and mitochondrial disease;

[0131] vi) tumor diseases;

[0132] vii) Cardiovascular disease leading to heart failure.

[0133] In one embodiment, the second composition comprising propionic acid can also treat and / or prevent the occurrence of ketoacidosis. In a specific embodiment, the second composition comprising propionic acid is particularly suitable for subjects with uncontrolled diabetes and / or following a ketogenic diet. In one embodiment, the subject is starting or gradually increasing the use of a ketogenic diet to enter a therapeutic ketosis state.

[0134] According to the present invention the first and second compositions are not the same composition, the first composition does not comprise propionic acid and the second composition does not comprise any of acetic acid, butyric acid, caproic acid, citrate, nicotinamide riboside and nicotinamide.

[0135] The subject is preferably a human subject in therapeutic need of ketosis.

[0136] First composition

[0137] fatty acid

[0138] Preferably, the first composition comprises lipids, and these lipids comprise one or more fatty acids with less than six carbon atoms. Fatty acids that are not attached to other molecules are referred to as free fatty acids (FFA). In a preferred embodiment, the fatty acids as used in the composition of the present invention are unbranched, more preferably unbranched and have an even number of carbon atoms. Most preferably, the first composition comprises fatty acids containing two carbon atoms (acetic acid or acetate) and / or four carbon atoms (butyric acid or butyrate) and / or six carbon atoms (hexanoic acid and / or hexanoate). The first composition preferably comprises at least one of butyric acid or hexanoic acid and optional acetic acid. Preferably, the first composition does not comprise C8 or higher fatty acids.

[0139] These fatty acids can be present in the first composition as free fatty acids or in the form of lipids comprising these fatty acids. In the context of the present invention, when referring to the amount of fatty acids, if different sources or derivatives are used, these amounts are calculated by the (weight) amount of the corresponding short-chain fatty acids.

[0140] The lipids comprising fatty acids, as preferably used in the present invention, are preferably selected from the group consisting of triglycerides, diglycerides, monoglycerides, glycolipids, phospholipids and lysophospholipids. In one embodiment, the composition of the present invention comprises triglycerides containing fatty acyl chains and / or phospholipids containing fatty acyl chains, more preferably triglycerides containing fatty acyl chains. The triglycerides of the present invention preferably have at least one, more preferably at least two, even more preferably 3 fatty acyl chains.

[0141] Lipids with fatty acyl chains are degraded by lingual, gastric, duodenal (ie pancreatic) and small intestinal lipases. Thus, administration of lipids containing fatty acyl chains results in the release of fatty acids in the stomach, duodenum, jejunum and ileum.

[0142] The preferred source of fatty acyl chains is by chemical synthesis. The source of these lipids can be one or more of animals, plants, fermented products, microalgae, GMO, non-GMO or their mixtures. An alternative is the lipid obtained from the milk of non-human mammals, preferably cow's milk, goat's milk, sheep's milk, horse's milk, buffalo's milk, yak's milk, reindeer's milk, donkey's milk and camel's milk, particularly cow's milk and / or goat's milk. Milk lipids are sometimes also referred to as milk fat or butter fat. In a preferred embodiment, the lipid comprising short-chain fatty acyl chains is synthesized by glycerol and short-chain fatty acids through an enzyme (e.g., esterase). Examples are triacetin and tributyrin.

[0143] The first composition comprises at least one of butyric acid or caproic acid and optionally acetic acid. In one embodiment, when acetic acid is present in the first composition, the acetic acid is present in a therapeutically effective amount to increase ketone production in a subject on a ketogenic diet, maintain and / or improve ketosis and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet. In other embodiments, acetic acid is present in a therapeutically effective amount for (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet.

[0144] The ketogenic diet referred to in the context of the present invention preferably has a ketogenic weight ratio between 1:1 and 4:1.

[0145] Acetic acid is preferably present in the first composition in an amount to provide a daily dose of acetic acid in the range of 0.5 mg to 30 mg per kg body weight per day, preferably 1.5 mg to 7.5 mg per kg body weight per day, more preferably 2.0 mg to 3.0 mg per kg body weight per day.

[0146] In one embodiment, acetic acid is present in the first composition in the form of a triglyceride, triacetin or glyceroltriacetate. Triacetin, if present, is preferably present in the first composition in an amount to provide a daily dose of triacetin in the range of 0.6 mg to 36 mg per kg body weight per day, preferably 3 mg to 9 mg per kg body weight per day, more preferably 2.4 mg to 3.6 mg per kg body weight per day.

[0147] In a specific embodiment, the first composition is for a subject following a ketogenic diet. In one embodiment, when acetic acid is provided in the first composition, the acetic acid will be used and used with the ketogenic diet. The acetic acid is preferably provided in a range of 0.005 mg to 0.7 mg acetic acid per kcal of the ketogenic diet, more preferably 0.01 mg to 0.4 mg acetic acid per kcal of the ketogenic diet, and even more preferably 0.02 mg to 0.2 mg acetic acid per kcal of the ketogenic diet.

[0148] In one embodiment, when butyric acid is present in the first composition, the butyric acid is present in a therapeutically effective amount to increase ketone production in a subject on a ketogenic diet, maintain and / or improve ketosis, and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet. In another preferred embodiment, when butyric acid is present in the first composition, the butyric acid is present in a therapeutically effective amount for (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet.

[0149] Butyric acid is preferably present in the first composition in an amount to provide a daily dosage of butyric acid in the range of 0.2 mg to 12 mg per kg body weight per day, preferably 1 mg to 6 mg per kg body weight per day, more preferably 1.5 mg to 3 mg per kg body weight per day.

[0150] In one embodiment, butyric acid is present in the first composition in the form of a triglyceride, tributyrin or glyceroltributyrate. Tributyrin, if present, is preferably present in the first composition in an amount to provide a daily dose of tributyrin in the range of 0.2 mg to 14 mg per kg body weight per day, preferably 1 mg to 7 mg per kg body weight per day, more preferably 2 mg to 5 mg per kg body weight per day.

[0151] In a specific embodiment, the first composition is for a subject following a ketogenic diet. In one embodiment, when butyric acid is provided in the first composition, the butyric acid will be used and used with the ketogenic diet. The butyric acid is provided in a range of preferably 0.002 mg to 0.3 mg butyric acid per kcal of the ketogenic diet, more preferably 0.015 mg to 0.2 mg butyric acid per kcal of the ketogenic diet, and even more preferably 0.01 mg to 0.1 mg butyric acid per kcal of the ketogenic diet.

[0152] Hexanoic acid

[0153] In one embodiment, the first composition comprises caproic acid.

[0154] Therefore, in one embodiment, at least one of caproic acid or butyric acid and optionally acetic acid is provided for the following therapeutic uses:

[0155] (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet, wherein at least one of the caproic acid or butyric acid and optionally acetic acid is contained in a non-ketogenic amount in the first composition, or at least one of the caproic acid or butyric acid and optionally acetic acid is provided in a non-ketogenic amount by a dietary fiber blend contained in the first composition. The therapeutic use involves a) administering the first composition, b) optionally, administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid under the premise that the blood ketone level is above 3mmol / L.

[0156] In one embodiment, when caproic acid is present in the first composition, the caproic acid is present in a therapeutically effective amount to increase ketone production, maintain and / or improve ketosis in a subject on a ketogenic diet, and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet. Caproic acid, when present, may

[0157] (i) controlling and / or modulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or modulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet.

[0158] Caproic acid is preferably present in the first composition in an amount to provide a daily dose of caproic acid in the range of 6 to 165 mg per kg body weight per day, preferably 30 to 85 mg per kg body weight per day, more preferably 50 to 70 mg per kg body weight per day.

[0159] In one embodiment, caproic acid is present in the first composition in the form of a triglyceride, trihexanoin or glyceroltrihexanoate. Trihexanoin, if present, is preferably present in the first composition in an amount to provide a daily dose of trihexanoin in the range of 5 to 185 mg per kg body weight per day, preferably 35 to 90 mg per kg body weight per day, more preferably 50 to 75 mg per kg body weight per day.

[0160] In one embodiment, when caproic acid is provided in the first composition, the caproic acid will be used and used with a ketogenic diet. The range of providing caproic acid is preferably 0.16 mg to 1.6 mg caproic acid per kcal ketogenic diet, more preferably 0.3 mg to 1.2 mg caproic acid per kcal ketogenic diet, and even more preferably 0.6 mg to 0.8 mg caproic acid per kcal ketogenic diet.

[0161] Dietary fiber as a source of fatty acids

[0162] In alternative embodiments of the present invention, the source of fatty acids is dietary fiber. In one embodiment, acetic acid and butyric acid can be provided by microbial fermentation of dietary fiber in the colon. In one embodiment, dietary fiber is provided in the first composition in an amount sufficient to provide acetic acid and butyric acid within the therapeutically effective range. In one embodiment, 1 g to 2 g of dietary fiber is provided per 100 kcal total diet.

[0163] In a preferred embodiment, the dietary fiber in the non-ketogenic ketogenic diet-enhancer composition serves as a substrate for producing fatty acids. In the context of the present invention, the dietary fiber that serves as a substrate for fatty acids is a butyrate dietary fiber or a butyrate dietary fiber blend. The butyrate dietary fiber or blend produces more caproate and butyrate than propionate and valerate FA when fermented. For the purposes of this specification, since the production of valerate and caproate is negligible in any case, the butyrate dietary fiber used in the present invention is defined as a dietary fiber or a dietary fiber blend that can produce butyrate and propionate in a beneficial ratio. As used herein, the beneficial weight ratio of butyrate to propionate is defined as butyrate is more than propionate, that is, the weight ratio of butyrate to propionate is at least 1, preferably at least 1.1.

[0164] A butyrate-producing dietary fiber that can serve as a substrate for producing fatty acids, preferably producing acetate, butyrate, propionate and caproate, more preferably producing propionate and butyrate in a beneficial ratio, thereby being able to increase ketone production in a subject on a ketogenic diet, maintain and / or improve ketosis and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet.

[0165] As used herein, the expression "beneficial butyrate to propionate ratio" means that the weight of butyrate produced by fermentation of a fiber or fiber mixture is at least equal to or greater than the amount of propionate produced by fermentation. For example, locust bean gum or yeast beta-glucan produce more propionate than butyrate when fermented, and thus these fibers have a butyrate to propionate ratio below 1 and do not enhance or increase ketone production. In contrast, soy fiber and inulin are exemplary fibers that have a beneficial butyrate to propionate ratio when fermented.

[0166] In a preferred embodiment, the fermentation of butyrate-producing dietary fiber beneficially results in the production of fatty acids, wherein butyrate and propionate are produced in a weight ratio of butyrate: propionate of at least 1, preferably at least 1.1. The fermentation characteristics of dietary fiber and the accompanying butyrate to propionate ratio produced by a single source fiber or a fiber blend can be evaluated by fermentation assays known in the art. An exemplary method for evaluating fiber fermentation includes the use of an in vitro fermentation model using a pool of fecal samples from healthy adults exposed to about 10 mg / ml of fiber for 24 hours at 37°C under anaerobic conditions.

[0167] In one embodiment, every 100 kcal total diet provides 1 g to 2 g of dietary fiber. In one embodiment, in a diet of about 2500 kcal per day, 25 g to 50 g of dietary fiber is provided, which can provide about 10 μM to about 250 μM of fatty acids, including C2, C4 and C6 fatty acids, in the blood.

[0168] The dietary fiber providing acetic acid, butyric acid and / or caproic acid is a fermentable dietary fiber, such as fermentable oligosaccharides and polysaccharides. Preferably, the dietary fiber is a butyrate dietary fiber with beneficial fermentation characteristics, wherein butyrate and propionate are produced in a weight ratio of C4:C3 of at least 1, preferably at least 1.1. These fermentable fibers may include, but are not limited to, pectin, mucilage, gum, galacto-oligosaccharide, oligofructose, inulin, polyfructose, oligofructose, arabinogalactan, hemicellulose, oligosaccharides, resistant starch, soy fiber (soluble soy polysaccharide) or mixtures thereof.

[0169] In one embodiment, the butyrate-producing dietary fiber serving as a substrate for producing fatty acids is a fermentable fiber selected from the group consisting of pectin, mucilage, gum, galacto-oligosaccharide, oligofructose, inulin, polyfructose, oligofructose, arabinogalactan, (hemi)cellulose, resistant starch, soy fiber, oligosaccharides and mixtures thereof.

[0170] In certain embodiments, a fiber blend is preferably used. Exemplary fiber blends used in the context of the present invention are fermentable blends and provide a beneficial C4:C3 weight ratio of at least 1, preferably at least 1.1, and even more preferably at least 1.5. An exemplary fiber blend is a fiber mixture comprising a) β-galacto-oligosaccharides, b) inulin, c) resistant starch, and / or d) soluble soy polysaccharides, and provides fatty acids, particularly in a beneficial C4:C3 weight ratio.

[0171] Another exemplary fiber blend comprises a) FOS, b) inulin, c) soy fiber, d) resistant starch, e) gum arabic and / or f) cellulose. The blend is fermentable and provides fatty acids, particularly fatty acids in a beneficial C4:C3 weight ratio of at least 1, preferably at least 1.1, and even more preferably at least 1.5.

[0172] Another exemplary fiber blend comprises a) arabinoxylan, b) oat beta-glucan, c) pectin and / or d) resistant starch. The fiber mixture is fermentable and produces butyrate and propionate in a C4:C3 weight ratio of at least 1, preferably at least 1.1, and even more preferably at least 1.5.

[0173] Therefore, in one embodiment, at least one of caproic acid or butyric acid and optionally acetic acid is provided for the following therapeutic uses:

[0174] (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet, wherein at least one of the caproic acid or butyric acid and optionally acetic acid is contained in a non-ketogenic amount in the first composition, or the at least one of the caproic acid or butyric acid and optionally acetic acid is provided in a non-ketogenic amount by the dietary fiber blend contained in the first composition.

[0175] The therapeutic use involves a) administering the first composition, b) optionally, administering a second composition comprising propionic acid to reduce ketone production / administering the second composition comprising propionic acid when the blood ketone level is above 3 mmol / L.

[0176] Thus, in further embodiments, at least one of caproic acid or butyric acid and optionally acetic acid is provided for therapeutic use in (i) enhancing ketosis and / or (ii) preventing and / or treating resistance to a ketogenic diet in a subject following / adopting a ketogenic diet, wherein the at least one of caproic acid or butyric acid and optionally acetic acid is contained in a non-ketogenic amount in the first composition, or the at least one of caproic acid or butyric acid and optionally acetic acid is provided in a non-ketogenic amount by a dietary fiber blend contained in the first composition.

[0177] Citrate

[0178] In other embodiments, the first composition may further comprise citric acid or a citrate. Citrate is converted to isocitrate in the first step of the Krebs cycle (also known as the citric acid or TCA cycle). The citrate used in the first composition is preferably in combination with potassium (K + ), sodium (Na + ), magnesium (Mg 2+ ) or calcium (Ca 2+ In the context of the present invention, these amounts are calculated based on the (weight) amount of the corresponding citrate salt.

[0179] Thus, in one embodiment, at least one of caproic acid or butyric acid and optionally acetic acid is provided in a therapeutically effective amount for use in a subject following / adopting a ketogenic diet.

[0180] (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or

[0181] (ii) controlling and / or regulating ketone body production associated with a ketogenic diet,

[0182] Wherein at least one of the caproic acid or butyric acid and optionally acetic acid is contained in a non-ketogenic amount in the first composition, or at least one of the caproic acid or butyric acid and optionally acetic acid is provided in a non-ketogenic amount by a dietary fiber blend contained in the first composition, wherein the first composition optionally further comprises a therapeutically effective amount of citrate. The therapeutic use involves a) administering the first composition, b) optionally, administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid under the premise that the blood ketone level is higher than 3mmol / L.

[0183] In one embodiment, when citrate is present in the first composition, the citrate is present in a therapeutically effective amount to increase ketone production in a subject on a ketogenic diet, maintain and / or improve ketosis and / or prevent or treat tolerance to a ketogenic diet in a subject on a ketogenic diet. In another embodiment, when citrate is present in the first composition, the citrate is present in a therapeutically effective amount for (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet.

[0184] Citrate, if present, is preferably present in the first composition in an amount to provide a daily dose of citrate in the range of 0.01 g to 0.4 g per kg body weight per day, preferably 0.04 g to 0.15 g per kg body weight per day, more preferably 0.08 g to 0.1 g per kg body weight per day.

[0185] In one embodiment, when citrate is provided in the first composition, the citrate will be used and used with the ketogenic diet. The range of providing citrate is preferably 0.1 mg to 10 mg citrate per kcal ketogenic diet, more preferably 0.25 mg to 7 mg citrate per kcal ketogenic diet, and even more preferably 0.4 mg to 3.5 mg citrate per kcal ketogenic diet.

[0186] In one embodiment, the first composition comprises butyric acid, caproic acid, and citrate.

[0187] Less than 15 g / day K + / Na + / Mg + - Citrate and possibly less than 20g / day of Ca 2+ - Daily intake of citrate is considered safe and does not pose a risk of electrolyte imbalance.

[0188] Nicotinamide riboside

[0189] The present disclosure provides a first composition further comprising a NAD+ precursor selected from the group consisting of tryptophan, nicotinic acid (nicotinic acid or niacin), nicotinamide (nicotinamide or niacinamide), nicotinic acid riboside (NaR), nicotinamide riboside (NR) and mixtures thereof. In a preferred aspect, the first composition may comprise nicotinamide riboside (NR and / or nicotinamide). In the context of the present invention, these amounts are calculated based on the (weight) amount of the corresponding nicotinamide riboside.

[0190] As used herein, "nicotinamide riboside" includes derivatives thereof, such as L-valine ester and L-phenylalanine ester of nicotinamide riboside.

[0191] Thus, in one embodiment, at least one of caproic acid or butyric acid and optionally acetic acid is provided in a therapeutically effective amount for use in a subject following / adopting a ketogenic diet.

[0192] (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or

[0193] (ii) controlling and / or regulating ketone body production associated with a ketogenic diet,

[0194] Wherein at least one of the caproic acid or butyric acid and optionally acetic acid is contained in a non-ketogenic amount in the first composition, or at least one of the caproic acid or butyric acid and optionally acetic acid is provided in a non-ketogenic amount by a dietary fiber blend contained in the first composition, wherein the first composition optionally further comprises a therapeutically effective amount of a NAD+ precursor selected from nicotinic acid, nicotinamide riboside and / or nicotinamide, preferably nicotinamide riboside and / or nicotinamide. The therapeutic use involves a) administering the first composition, b) optionally, administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid under the premise that the blood ketone level is higher than 3mmol / L.

[0195] In one embodiment, when nicotinamide riboside or nicotinamide is present in the first composition, the nicotinamide riboside is present in a therapeutically effective amount to increase ketone production, maintain and / or improve ketosis and / or prevent or treat tolerance to the ketogenic diet in a subject on a ketogenic diet. In a further aspect, when nicotinamide riboside or nicotinamide is present in the first composition, the nicotinamide riboside or nicotinamide is present in a therapeutically effective amount for (i) controlling and / or regulating ketosis associated with a ketogenic diet and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following / adopting a ketogenic diet.

[0196] Nicotinamide riboside, if present, is preferably present in the first composition in an amount to provide a daily dose of nicotinamide riboside in the range of 0.5 mg to 15 mg per kg body weight per day, preferably 1 mg to 5 mg per kg body weight per day, more preferably 2.5 mg to 3.5 mg per kg body weight per day.

[0197] In one embodiment, when nicotinamide riboside is provided in the first composition, nicotinamide riboside will be used and used with a ketogenic diet. Nicotinamide riboside is provided in a range preferably of 0.01 mg to 0.4 mg nicotinamide riboside per kcal ketogenic diet, more preferably 0.015 mg to 0.25 mg nicotinamide riboside per kcal ketogenic diet, and even more preferably 0.02 mg to 0.1 mg nicotinamide riboside per kcal ketogenic diet.

[0198] In one embodiment, the first composition comprises butyrate, hexanoate, citrate, and a NAD+ precursor.

[0199] Second composition (comprising propionate)

[0200] Propionic acid or propionate according to the invention can be present as free fatty acid, as lipids comprising these fatty acids or as physiologically acceptable derivatives thereof. Propionic acid is preferably present in the second composition, wherein propionic acid is present as an active ingredient. In one aspect of the invention, this second composition consists essentially of propionic acid.

[0201] In one embodiment, the second composition comprises a therapeutically effective amount of propionic acid or a derivative thereof, which is present in the form of a lipid comprising propionic acid. The lipid comprising propionic acid is preferably selected from the group consisting of: triglycerides, diglycerides, monoglycerides, glycolipids, phospholipids and lysophospholipids. In one embodiment, the composition of the present invention comprises triglycerides containing fatty acyl chains and / or phospholipids containing fatty acyl chains, more preferably triglycerides containing fatty acyl chains. The triglycerides of the present invention preferably have at least one, more preferably at least two fatty acyl chains, which are preferably located at the sn-3 position. In one embodiment, propionate can be present in the form of a glycerol derivative monopropionate, dipropionate or tripropionate, preferably in the form of tripropionate.

[0202] Lipids with fatty acyl chains are degraded by lingual, gastric, duodenal (ie pancreatic) and small intestinal lipases. Thus, administration of lipids containing fatty acyl chains results in the release of fatty acids in the stomach, duodenum, jejunum and ileum.

[0203] In one embodiment, the second composition comprises a physiologically acceptable salt form of propionic acid, such as calcium propionate, potassium propionate, sodium propionate, magnesium propionate, ammonium propionate.

[0204] In another embodiment, the second composition comprises propionic acid in the form of an organic propionic ester, such as methyl, ethyl, propyl or isopropyl ester, such as ethyl propionate. Such esters may be naturally occurring or may be obtained by chemical reactions, such as condensation of SCFA with a suitable alcohol (e.g., ethanol).

[0205] Propionic acid is provided in an amount that provides a daily dose of propionic acid in the range of 1 mg to 1200 mg per day, preferably 5 mg to 600 mg per day, more preferably 10 mg to 400 mg per day.

[0206] In one embodiment, propionic acid is provided in the form of a triglyceride (such as tripropionin or glycerol tripropanoate) in an amount that can provide a daily dosage in the range of 1 mg to 1400 mg per day, preferably 6 to 700 mg per day, more preferably 12 to 500 mg per day.

[0207] Alternatively, propionic acid is provided in the form of a diglyceride (such as dipropionin or glyceroldipropanoate) in an amount to provide a daily dose in the range of 1 mg to 1700 mg per day, preferably 5 to 1000 mg per day, more preferably 15 to 600 mg per day.

[0208] In a further alternative embodiment, propionic acid is provided in the form of a monoglyceride (such as monopropionin or glycerol monopropanoate) in an amount to provide a daily dosage in the range of 2 mg to 2400 mg per day, preferably 10 to 1200 mg per day, and more preferably 20 to 800 mg per day.

[0209] In one embodiment, a mixture of monopropionic acid, dipropionic acid and / or tripropionic glycerol provides propionic acid according to the present invention.

[0210] In a specific embodiment, the second composition comprising propionic acid is for a subject following a ketogenic diet. Propionic acid will be used and used with a ketogenic diet. Propionic acid is preferably provided in the range of 0.002 mg to 0.3 mg propionic acid per kcal of the ketogenic diet, more preferably 0.01 mg to 0.15 mg propionic acid per kcal of the ketogenic diet, and even more preferably 0.02 mg to 0.1 mg propionic acid per kcal of the ketogenic diet.

[0211] Alternatively, propionic acid is provided in the form of a triglyceride (such as tripropionin or glyceroltripropanoate) in an amount ranging from 0.002 mg to 0.4 mg tripropionin per kcal of the ketogenic diet, more preferably from 0.01 mg to 0.18 mg tripropionin per kcal of the ketogenic diet, and even more preferably from 0.02 mg to 0.1 mg tripropionin per kcal of the ketogenic diet.

[0212] In another alternative embodiment, propionic acid is provided in the form of a diglyceride (such as dipropionin or glycerol dipropanoate) in an amount ranging from 0.003 mg to 0.4 mg of dipropionin per kcal of the ketogenic diet, more preferably from 0.015 mg to 0.2 mg of dipropionin per kcal of the ketogenic diet, and even more preferably from 0.02 mg to 0.1 mg of dipropionin per kcal of the ketogenic diet.

[0213] In another embodiment, propionic acid is provided in the form of a monoglyceride (such as monopropionin or glycerol monopropanoate) in an amount ranging from 0.004 mg to 0.6 mg of monopropionin per kcal of the ketogenic diet, more preferably from 0.02 mg to 0.3 mg of monopropionin per kcal of the ketogenic diet, and even more preferably from 0.06 mg to 0.1 mg of monopropionin per kcal of the ketogenic diet.

[0214] Administration forms of the first and second compositions

[0215] The first and second compositions of the present invention may be in any form suitable for enteral, oral or parenteral administration. Non-limiting examples of parenteral administration include intravenous, intramuscular, intraperitoneal, subcutaneous, intraarticular, intrasynovial, intraocular, intrathecal, topical and inhalation.

[0216] In one aspect of the invention, the first and second compositions according to the invention may be used as a medicament comprising one or more pharmaceutically acceptable carrier materials.

[0217] In a preferred aspect, the first and second compositions according to the invention can be used as a nutritional product, for example as a nutritional supplement, for example as an additive to a ketogenic diet, as a enhancer, added to a ketogenic diet.

[0218] Supplements (preferably for enteral applications) can be solid or liquid galenic formulations. Examples of solid galenic formulations are tablets, capsules (e.g., hard or soft shell gelatin capsules), pills, sachets, powders, granules, etc., which contain active ingredients and conventional galenic carriers. Any conventional carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier material suitable for oral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, etc. In addition, additives such as flavoring agents, preservatives, stabilizers, emulsifiers, buffers, etc. can be added according to the conventional practices of nutrition and drug formulation.

[0219] The first and second compositions according to the invention may also be used as nutritional products for use in conjunction with tube feeding, for example as an additive to tube feeding, for intermittent or optionally continuous administration.

[0220] The first and second compositions may comprise a daily dose of one or more dosage units. The dosage unit may be in liquid form or solid form, and in both cases, the daily dose may be provided by one or more dosage units, such as one or more drinks, capsules or tablets. The ketogenic booster composition may be administered simultaneously with the ketogenic diet or separately or continuously at a time interval.

[0221] The subject may receive one or more doses of the first composition per day, preferably 1 to 6 times per day, more preferably 3 to 4 times per day. In some embodiments, the administration will continue for the rest of the individual's life. The subject using the first composition may receive one or more doses (or portions) of the first composition per day, preferably 1 to 6 times per day, more preferably 3 to 4 times per day.

[0222] One skilled in the art can determine the ideal duration and order of administering the first and second compositions.

[0223] In a specific non-limiting example, for a subject weighing 70 kg, consuming a ketogenic diet of 3000 kcal per day, with a ketogenic ratio of 1:1 to 4:1, the daily dose of the first composition may be as follows:

[0224] Acetic acid or its derivatives: between 35 mg / day and 2520 mg / day;

[0225] Butyric acid or its derivatives: between 7 mg / day and 980 mg / day;

[0226] Hexanoic acid or its derivatives: between 455 mg / day and 12.95 g / day;

[0227] Citrate: between 0.7 g / day and 20 g / day;

[0228] NR: between 42 mg / day and 1015 mg / day.

[0229] In another non-limiting example, for a subject weighing 70 kg, consuming a ketogenic diet of 3000 kcal per day, a ketogenic ratio of 1:1 to 4:1, and using the first composition according to the present invention, the daily dose of the second composition may be as follows:

[0230] Propionic acid: between 3000 kcal / day*(0.002 mg to 0.3 mg propionic acid per kcal) = 6 mg to 900 mg C3 / day.

[0231] In another embodiment, a first composition is provided that provides essentially

[0232] (i) 1 mg to 1.2 g butyric acid / day; and optionally one or more of the following:

[0233] (ii) 32.5 mg to 16.3 g caproic acid per day;

[0234] (iii) 0.05 g to 20 g citrate / day;

[0235] (iv) 3 mg to 1.45 g nicotinamide riboside per day; and

[0236] (v) 2.5 mg to 3 g acetic acid per day.

[0237] These ranges refer to total amounts per 24-hour period.

[0238] In another embodiment, a second composition is provided, which essentially provides

[0239] (i) 1 mg to 1200 mg of propionic acid per day. This range refers to the total amount per 24 hours.

[0240] In one embodiment, there is provided a first composition according to the present invention, each serving consisting essentially of the following, based on the dry weight of the composition:

[0241] (i) 0.2 mg to 1.2 g butyric acid;

[0242] (ii) 5 mg to 17 g caproic acid;

[0243] (iii) 10 mg to 20 g of citrate; and

[0244] (iv) 0.5 mg to 1.5 g nicotinamide riboside.

[0245] In another embodiment, a first composition is provided, wherein each serving, based on the dry weight of the composition, consists essentially of

[0246] (i) 0.2 mg to 1.2 g butyric acid;

[0247] (ii) 5 mg to 17 g caproic acid;

[0248] (iii) 10 mg to 20 g of citrate;

[0249] (iv) 0.5 mg to 1.5 g nicotinamide riboside; and

[0250] (v) 0.5 mg to 3 g of acetic acid.

[0251] In one embodiment, a first composition is provided, intended for administration 4 to 6 times per day, each serving consisting essentially of

[0252] (i) 0.1-0.3 mg butyric acid;

[0253] (ii) 4.6-5.4 mg hexanoic acid;

[0254] (iii) 9-11 mg citrate; and

[0255] (iv) 0.4-0.6 mg nicotinamide riboside. Optionally, the first composition intended for administration 4 to 6 times per day additionally consists essentially of (v) 0.4-0.6 mg acetic acid.

[0256] In a further embodiment, a first composition is provided, intended for once daily administration, each serving consisting essentially of

[0257] (i) about 1.2 g butyric acid;

[0258] (ii) about 17 g caproic acid;

[0259] (iii) about 20 g citrate; and

[0260] (iv) about 1.5 g nicotinamide riboside. Optionally, the first composition, intended for once daily administration, additionally consists essentially of (v) about 3 g acetic acid.

[0261] Typically, a serving of the first composition is between about 10 g and 25 g.

[0262] In a further embodiment, there is provided a first composition according to the invention consisting essentially of the following on a dry weight basis:

[0263] (i) 20 mg to 1.2 g of acetic acid;

[0264] (ii) 4 mg to 480 mg butyric acid;

[0265] (iii) 260 mg to 3.3 g caproic acid;

[0266] (iv) 0.2 mg to 4.4 g citrate; and

[0267] (v) 12 mg to 286 mg nicotinamide riboside,

[0268] wherein the weight ratio of acetic acid to butyric acid: caproic acid is between 1:1.8 and 1:2.1, preferably between 1:1.9 and 1:2.0;

[0269] The weight ratio of acetic acid and butyric acid:citrate is between 1:2.4 and 1:2.7, preferably between 1:2.5 and 1:2.6; and

[0270] The weight ratio of acetic acid and butyric acid: nicotinamide riboside is between 1:0.15 and 1:0.19, preferably between 1:0.16 and 1:0.18, and wherein the total weight of the composition is between about 10-20 g.

[0271] The first and second compositions are formulated as dietary supplements for a ketogenic diet.

[0272] Further provided herein are kits.

[0273] A kit is provided which includes:

[0274] 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1;

[0275] 2) providing a first composition of at least one of caproic acid or butyric acid and optionally acetic acid;

[0276] 3) A second composition comprising propionic acid.

[0277] The kit optionally further comprises 4) means for measuring ketone levels in a body fluid.

[0278] Also provided herein is a kit for use in (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following a ketogenic diet, the kit comprising:

[0279] 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1;

[0280] 2) providing a first composition of at least one of caproic acid or butyric acid and optionally acetic acid;

[0281] 3) A second composition comprising propionic acid.

[0282] The kit for (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following a ketogenic diet optionally further comprises 4) a means for measuring ketone levels in a body fluid.

[0283] It should be understood that a kit is a series of compositions according to the present invention that are conceptually related to each other. The individual components of the kit do not have to be packaged together.

[0284] Examples

[0285] For a more complete understanding of the present disclosure, reference is now made to the following examples in conjunction with the accompanying drawings.

[0286] Example 1

[0287] An assay was used to measure ketone production in mouse hepatocytes (Hepa1-6 cell line), where cells were first grown to a monolayer (growth phase), then exposed to starvation to deplete cellular lipid stores, and then entered a ketogenic phase, where cells were cultured with oleic acid or a ketogenic dietary fat blend in the presence or absence of one or more of C2, C4, C6 fatty acids, citrate, and nicotinamide riboside (also referred to herein as C2, C4, C6, citrate, and NR). Ketone body production was then determined by measuring β-hydroxybutyrate in the cell culture medium according to the details described below:

[0288] Growth phase: cells were grown at 90,700 cells / cm 2 The cells were seeded in 6-well plates at a concentration of 1:1 and grown for 24 h at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5 mM glucose, 10% fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM pyruvate, and antibiotics (1% penicillin and streptomycin).

[0289] Starvation phase: At the end of the growth phase, the cells form a monolayer. The medium is changed to DMEM containing 1 mM glucose and antibiotics (1% penicillin and streptomycin) but without FBS. The medium is further supplemented with L-carnitine (a cofactor required for the uptake of fatty acids by mitochondria, where they are converted into ketones). The cells are incubated in this medium for 24 hours. During this time, the cells are extremely deprived of glucose, lipids and hormones contained in FBS, forcing them to consume and empty their lipid stores. Thus, any interference with nutrient assays is avoided. In addition, the starvation phase is believed to induce specific metabolic changes that maximize ketone production.

[0290] Ketogenic phase: At the end of the starvation phase, the culture medium was changed to Krebs-Henseleit buffer (KHB) supplemented with test nutrients (single fatty acids and fatty acid blends shown in Table 1) and L-carnitine.

[0291] The fatty acid blend contained a fatty acid composition similar to that used in the ketogenic diet (K-one). The content of each fatty acid in the blend is given as a molar ratio to oleic acid (OA), where the molar content of oleic acid is set to 1. Table 1 shows the concentration of each fatty acid in a 100 μM blend. Dilutions of this blend were used to determine Figure 1B and Figure 1D Dose response curve in . C2 and C4 were not included in this blend.

[0292] Table 1 Composition of fatty acid blends.

[0293]

[0294]

[0295] KHB is composed of salt and bicarbonate, as a chemical buffer, osmotic pressure and acidity (pH) are maintained at physiological levels. Before measuring, medium and long chain fatty acids are coupled to bovine serum albumin, so that they are soluble in KHB and allow them to be effectively taken up by these cells. This coupling is physiological, because in the human body, medium and long chain fatty acids are also normally coupled to albumin, so as to be transported in the blood circulation. Short chain fatty acids (C2, C4) are not coupled to albumin in this assay, because they are water-soluble and can circulate freely in the human body. These cells are incubated at 37 ° C for 6 hours. During this period of time, they produce ketones by test nutrients, and other nutrients are almost not disturbed by this, and secrete β-hydroxybutyric acid (β-Hb) into this culture medium.

[0296] β-Hb measurement: At the end of the ketogenic phase, the entire culture medium was collected and dried by vacuum centrifugation at 21°C for 20 hours. The dried pellet was resuspended in a small amount of assay buffer to produce a β-Hb concentration 10-20 times higher than the culture medium. These samples were deproteinized using spin columns to measure the free unbound fraction of β-Hb. The β-Hb concentration was then measured by an enzymatic reaction that produced a fluorescent product (Cayman Chemicals 700740). Fluorescence was measured on a fluorescence microplate reader and was directly proportional to the β-Hb concentration in the sample (ranging from 0.1 μM to 50 μM β-Hb).

[0297] 1.1 Effect of C2 on Ketone Production

[0298] In the above ketone production assay, providing hepatocytes with C2 alone at concentrations of 1 μM, 5 μM, and 10 μM produced almost no bHB ( Figure 1A and Figure 1BWhen hepatocytes were incubated with a range of concentrations of oleic acid (OA), a dose-response curve for this long-chain fatty acid showed that the highest levels of ketone production over oleic acid (OA) alone were achieved at a concentration of 100 μM OA ( Figure 1C ). During ketogenic diet treatment, plasma concentrations of fatty acids in humans are typically above 100 μM. Therefore, to evaluate the ketogenic enhancing effects of C2, OA was assayed at a concentration of 100 μM. Combining 1 μM, 5 μM, or 10 μM C2 with 100 μM OA produced more βHb than 100 μM OA alone. The effects of the combination of C2 and OA on βHb production were non-additive, which could not be explained by the sum of the effects of C2 and OA on βHb production. Therefore, at physiological concentrations of 1 μM to 10 μM, C2 can enhance ketone production at the highest level of a single fatty acid.

[0299] The same experiment was performed on a fatty acid blend consisting of medium-chain, long-chain, and very long-chain fatty acids included in the ketogenic diet (denoted as K-one). The specific composition of this blend, excluding C2, is shown in Table 1. When hepatocytes were incubated with a range of concentrations of this blend, the dose-response curve showed that at a total fatty acid concentration of 100 μM, the blend produced maximal βHb ( Figure 1D ). Fatty acid concentrations in plasma of people on a ketogenic diet exceed 100 μM, which indicates that the maximum level of ketone production is achieved. Therefore, to evaluate the ketogenic enhancing effect of C2, the fatty acid blend was tested at a concentration of 100 μM. Combining 1 μM or 10 μM C2 with 100 μM fatty acid blend produced slightly more βHb than using an equimolar concentration of the fatty acid blend alone ( Figure 1B The effects of the combination of C2 and the fatty acid blend on βHb production were non-additive, as C2 alone did not produce βHb ( Figure 1B ). Thus, within the physiological concentration range of 1 μM to 10 μM, C2 can enhance βHb production at the highest level of the fatty acid blend included in the ketogenic diet.

[0300] In conclusion, low physiological concentrations of C2 from 1 μM to 10 μM can enhance the Figure 1A ) and a blend of fatty acids included in the ketogenic diet (K-one) ( Figure 1B ) of ketones (βHb). Because no ketones were produced when C2 was provided to hepatocytes alone, the effect of C2 could not be explained by its use as a substrate. In addition, both the single fatty acid (oleic acid) and the fat blend (K-one) were tested with C2 at a concentration of 100 μM, at which they both maximized ketone production on their own ( Figure 1C, Figure D). Thus, C2 enhances ketone production at the highest level for either a single fatty acid or a blend of fatty acids.

[0301] 1.2 Effect of C4 on Ketone Production

[0302] In the above ketone production assay, hepatocytes exposed to C4 alone at concentrations of 1 μM, 5 μM, and 10 μM produced almost no βHb ( Figure 2A and Figure 2B In this assay, the highest level of ketone production was achieved with incubation with OA alone at a concentration of 100 μM OA ( Figure 1C ). Because plasma concentrations of fatty acids in people on a ketogenic diet are usually above 100 μM, OA was measured at a concentration of 100 μM. 1 μM, 5 μM, or 10 μM C4 combined with 100 μM OA produced more βHb than 100 μM OA alone ( Figure 2A ). In addition, βHb production increased with increasing concentrations of C4 provided. The effects of the combination of C4 and OA on βHb production were non-additive and could not be explained by the sum of the effects of C4 and OA on βHb production. Thus, administration of C4 in the physiological concentration range of 1 μM to 10 μM enhanced ketone production at the highest level of a single fatty acid.

[0303] Next, the ketogenic enhancement effect of C4 on ketone production in a fatty acid blend included in a ketogenic diet (K-one) was evaluated. The fatty acid blend did not contain C4. 10 μM C4 combined with 100 μM fatty acid blend produced more βHb ( Figure 2B The increase in βHb production achieved by combining 10 μM C4 and 100 μM fatty acid blend was non-additive, as C4 alone did not produce βHb ( Figure 2B ).

[0304] Hepatocytes were also incubated with C4 at a fixed concentration of 10 μM and a fatty acid blend ranging from 1 μM to 100 μM contained in a ketogenic diet (K-one). Control hepatocytes were exposed to the same concentration range of this fatty acid blend without C4. As the concentration of the fatty acid blend approached 100 μM, C4 gradually enhanced the ketone production of the fatty acid blend ( Figure 2C). These results further demonstrate that low physiological concentrations of C4 can enhance βHb production from the fatty acid blend included in the ketogenic diet. To evaluate whether C4 can be used as a substrate for ketone synthesis at concentrations of 10 μM and below, a dose-response curve of C4 as a substrate for βHb production was obtained, covering a range of C4 concentrations from 1 μM to 100 μM. The dose-response curve shows that when the concentration exceeds 10 μM, C4 begins to be converted into βHb as a substrate ( Figure 2D ). This further confirms that at concentrations below 10 μM, C4 can act as a functional enhancer of ketone production from a single fatty acid or a fat blend, and not as a direct substrate for ketone synthesis.

[0305] In conclusion, C4 at low physiological concentrations ranging from 1 μM to 10 μM can enhance the Figure 2A ) and a blend of fatty acids included in the ketogenic diet (K-one) ( Figure 2B ) of ketones (βHb). The effect of C4 on total ketone production was significantly greater than the sum of the contributions of equimolar concentrations of C4 and the fat blend. Therefore, this is non-additive and cannot be explained by C4 being used as a substrate for ketone production in the concentration range of 1 μM to 10 μM. This is also supported by the dose-response curve for C4, which shows that at concentrations above 10 μM, C4 begins to be efficiently converted to ketones ( Figure 2D ). Thus, C4 in the low physiological concentration range of 1 μM to 10 μM can enhance the maximum level of ketone production from a single fatty acid or a blend of fatty acids.

[0306] 1.3 Effect of C6 on Ketone Production

[0307] The study found that C6 at low physiological concentrations ranging from 1 μM to 10 μM enhanced the expression of a single fatty acid (oleic acid, OA) ( Figure 3A ) and a blend of fatty acids included in the ketogenic diet (K-one) ( Figure 3B and Figure 3C ) of ketones (β-Hb). The effect of C6 on total ketone production from the fat blend was significantly greater than the sum of the contributions of equimolar concentrations of C6 and the fat blend to the total ketone production. Therefore, this is non-additive, so this cannot be explained by C6 being used as a substrate for ketone production in the concentration range of 1μM to 10μM. This is also supported by the dose-response curve for C6, which shows that at concentrations above 10μM, C6 begins to be efficiently converted to ketones ( Figure 3D). Therefore, the data indicate that C6 functionally upregulates ketone production over a concentration range of 1 μM to 10 μM. Both the single fatty acid (oleic acid) and the K-one fat blend were tested at a concentration of 100 μM, at which they both maximized ketone production on their own ( Figure 1C and Figure 1D ). The K-one fat blend contains trace amounts of C6 (Table 1). However, the C6 concentration in the 100 μM K-one blend is 20 to 200 times lower than the C6 concentration range that can enhance ketogenesis of the blend (1 μM to 10 μM). Although the trace amounts of C6 in the K-one fat blend may have already stimulated ketogenesis, our data show that the addition of C6 in a concentration range of 1 μM to 10 μM can further enhance the highest level of ketone production of the fatty acid blend. In summary, at low physiological concentrations between 1 μM and 10 μM, C6 can functionally enhance ketone production of a single fatty acid or a blend of fatty acids.

[0308] 1.4 Effect of citrate on ketone production

[0309] In similar experiments as detailed above for C2 and C4, citrate in the range of physiological to supraphysiological concentrations from 200 μM to 1000 μM was found to increase the fatty acid blend (K-one) contained in the ketogenic diet ( Figure 4A-4C ) ketone (βHb) production. This fatty acid blend (without citrate) was tested at a concentration of 100 μM (Table 1), at which it achieved the highest level of ketone production on its own ( Figure 1D The effect of citrate on total ketone production was significantly greater than the sum of the ketone production achieved by the same (equimolar) amount of citrate or the fat blend alone ( Figure 4A and Figure 4B In fact, citrate alone did not produce ketones, but when added to the fat blend, it increased the ketone production of the fat blend by about 10%-20% ( Figure 4A-4C ; Figure 4C Shown is the condition of 200 μM citrate Figure 4A and Figure 4B Mean effect of the experiments shown (*P<0.05). Thus, citrate can enhance ketone production at the highest level of the fatty acid blend included in the ketogenic diet.

[0310] 1.5 Effects of Nicotinamide Riboside on Ketone Production

[0311] An assay was developed to measure NAD+ replenishment by NAD+ precursors to NAD+ depleted mouse hepatocytes (Hepa1-6 cells) under ketogenic-like dietary conditions. In this assay, mouse hepatocytes were starved of glucose and depleted of NAD+ by incubation in a very low glucose (1 mM) medium without vitamin B3, Trp, and FBS, and supplemented with 10 nM of an NAD+ depleting drug called FK866. Thereafter, the cells were supplemented with NAD+ by administration of NR or NAM or niacin (provided as a combination of NAM and niacin in a 1:1 molar ratio) or Trp. At the end of this replenishment period, the cells were scraped and assayed using the EnzyChrom TM Extraction was performed using NAD+ extraction buffer in the NAD / NADH assay kit. The NAD+ content of these cells was determined using the same kit following the manufacturer's manual. The NAD+ measurement is based on a lactate dehydrogenase reaction in which NAD+ is reduced to NADH, which in turn reduces the Formazan (MTT) reagent. The intensity of the color of the reduction product measured at 565nm is proportional to the NAD+ concentration in the sample. The assay is highly specific for NAD+ and is minimally interfered with by NADP+ or NADPH (<1%).

[0312] The study found that FK866 treatment significantly depleted NAD+ in hepatocytes, with the consumption being approximately 70% of the baseline NAD+ content of untreated hepatocytes ( Figure 5A ; ****, P < 0.0001). In addition, the study found that providing NR could dose-dependently replenish NAD+ levels to this baseline level or above within 24 hours of treatment ( Figure 5A ; ****, P<0.0001). In addition, the study found that at a high concentration of 1 mM, NR increased the NAD+ content in NAD+-depleted hepatocytes, and its increase was significantly greater than that of equimolar amounts of NAM or niacin ( Figure 5A ; ****, P<0.0001); at lower concentrations below 150 μM, the increase was greater than that of equimolar amounts of niacin ( Figure 5C These differences were not due to changes in cell viability, as cell counts (determined by ATP content measurements) were equal between treatments ( Figure 5B ). Thus, in NAD+-depleted mouse hepatocytes, NR was more effective than NAM and niacin in replenishing NAD+.

[0313] To measure the effect of supplementing NAD+ in hepatocytes with NR on ketone production, mouse hepatocytes were nutrient-deprived in a medium containing low (1 mM) glucose and L-carnitine, but without fetal bovine serum, vitamin B3 (niacin, NA, NAM) or NAD+ precursors in the form of Trp, and treated with the NAD+ depleting drug FK866. These conditions created a ketogenic diet-like nutritional condition and depleted the cells of NAD+. After 18 hours of incubation, FK866 was removed from the medium and a range of NR concentrations were added to replenish NAD+ in the hepatocytes. After 24 hours, the cells were switched to Krebs-Henseleit buffer (KHB) containing L-carnitine and a range of concentrations (1 μM to 100 μM) of oleic acid (a long-chain fatty acid) for 6 hours to induce and measure the production and secretion of b-hydroxybutyrate (βHB) into the medium.

[0314] The study found that supplementation of NAD+-depleted hepatocytes with NR at concentrations of 10 μM, 150 μM, and 1000 μM increased ketone production at the highest level under nutritional conditions similar to a ketogenic diet ( Fig. 6A and Figure 6C ) and its NAD+ content ( Figure 6B ). Combined with the greater ability to replenish NAD+ levels (Figure 5), it is concluded that NR can sustain ketone production more effectively than NAM or niacin or Trp.

[0315] Effects of 2C3 on Ketone Production

[0316] C3 was tested in a physiological human plasma concentration range of 1 μM to 10 μM. C3 alone did not produce βHb at concentrations of 1 μM, 5 μM, and 10 μM. Fig. 7A and Figure 7B Evaluation of ketone production from oleic acid (OA) showed that ketone production reached maximum or saturation at a concentration of 100 μM OA ( Figure 7C ). In people who are on a ketogenic diet, the concentration of a single fatty acid in plasma is usually around 100 μM or higher. Figure 7C Based on the findings shown, it can be assumed that ketone production from oleic acid is maximized during KD treatment. Combining 1 μM C3 (data not shown), 5 μM C3, and 10 μM C3 with 100 μM OA produced less βHb than 100 μM OA alone ( Fig. 7A ). Thus, C3 provided within the physiological concentration range would reduce ketone production at the highest level of OA (achievable by ketogenic diet treatment). Thus, the addition of C3 to a ketogenic diet would reduce ketone production from a single fatty acid.

[0317] The ketogenic diet (denoted K-one) contained a blend of medium-chain, long-chain, and very-long-chain fatty acids that resulted in the highest levels of βHb production at a total fatty acid concentration of 100 μM ( Fig.7D ). In humans on a ketogenic diet, total fatty acid concentrations in plasma are well over 100 μM. Therefore, it can be assumed that during treatment with a ketogenic diet, hepatocytes reach maximum levels of ketone production using the fatty acid blend in the ketogenic diet. Therefore, this fatty acid blend was tested at a concentration of 100 μM. This blend did not contain C3 (Table 1). Combining 1 μM C3, 5 μM C3, and 10 μM C3 with 100 μM fatty acid blend reduced βHb production by more than 60% compared to providing 100 μM fatty acid blend alone ( Figure 7B In addition, C3 reduced βHb production at the highest level of 100 μM fatty acid blend in a dose-dependent manner ( Figure 7B ). Therefore, adding C3 to a ketogenic diet would reduce ketone production from the fatty acid blend contained in the ketogenic diet.

[0318] In summary, low physiological concentrations of 1 μM to 10 μM C3 or propionate can inhibit the metabolism of a single fatty acid (oleic acid, OA) ( Fig. 7A ) and the fatty acid blend contained in the ketogenic diet (denoted as K-one) ( Figure 7B ). Importantly, the fat blend did not contain C3 (Table 1), which means that the inhibitory effect was indeed caused by the administration of low concentrations of C3. In addition, the single fatty acid (oleic acid) and the fat blend (K-one) were tested with C3 at a concentration of 100 μM, at which they both maximized ketone production on their own ( Figure 7C , Fig.7D ) and would maximize ketone production in a person on a ketogenic diet. Thus, under ketogenic diet-like treatment conditions, C3 can suppress the highest level of ketone production for a single fatty acid or a blend of fatty acids.

[0319] Propionate activity assay

[0320] As described above, an assay for measuring ketone production in mouse hepatocytes (Hepa1-6 cell line) was used, in which cells were first grown to a monolayer (growth phase), then exposed to starvation to deplete cellular lipid stores, followed by a ketogenic phase, in which cells were cultured in the presence of oleic acid or a ketogenic dietary fat blend with or without the addition of propionic acid (C3). Cells were exposed to C3 during the 6-hour ketogenic phase to assess the short-term effects of C3, or during a 24-hour starvation phase plus a 6-hour ketogenic phase to assess the long-term effects of C3. The effects on cell viability were assessed by measuring the ATP content of these cells (representing the number of viable cells) using a bioluminescent assay.

[0321] Growth phase: cells were grown at 90,700 cells / cm 2 The cells were seeded in 6-well plates at a concentration of 1:1 and grown for 24 h at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5 mM glucose, 10% fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM pyruvate, and antibiotics (1% penicillin and streptomycin).

[0322] Starvation phase: At the end of the growth phase, the cells formed a monolayer. The medium was changed to DMEM containing 1 mM glucose and antibiotics (1% penicillin and streptomycin) but without FBS. The medium was further supplemented with L-carnitine (a cofactor required for mitochondrial uptake of fatty acids, where they are converted to ketones). The cells were further supplemented with C3 in a concentration range of 300uM to 10mM. The cells were incubated in this medium for 24 hours. The cells under control conditions were incubated in the same starvation medium (without the addition of C3).

[0323] Ketogenic phase: At the end of the starvation phase, the medium was replaced with Krebs-Henseleit buffer (KHB) supplemented with L-carnitine and C3 in a concentration range of 300uM to 10mM. Cells under control conditions were incubated in the same starvation medium (without C3). After 6 hours of incubation, the number of viable cells was measured by measuring ATP content using an ATP assay kit containing recombinant firefly luciferase and its substrate luciferin (provided by ThermoFischer, ATP assay kit, 200-1,000 assays, catalog number: A22066).

[0324] Calculation of the effect on cell viability: The effect of C3 on cell viability was determined by calculating the percentage of viable cells exposed to C3 to the viable cells under control conditions, with n = 8 replicates for each dose of C3. The statistically significant differences in the number of viable cells for each dose were assessed by t-test.

[0325] ATP is the energy source of all living cells and is involved in many important biochemical reactions. When cells die, they stop synthesizing ATP, and the existing ATP pool degrades rapidly. Therefore, ATP is widely accepted as a marker of living cells. The higher the ATP concentration, the more living cells there are. ATP determination is a procedure for measuring cell viability based on detecting ATP. All living cells, including bacteria, can be detected by ATP determination. Several detection methods can be used, such as colorimetry, fluorescence, and bioluminescence. In the present invention, the bioluminescence ATP assay is selected to measure cell viability because this method has higher sensitivity, simple and consistent protocols, and fast and accurate results.

[0326] 2.1 Effects of propionate on cell viability and cytotoxicity

[0327] Evaluation of the cytotoxic effects of C3 showed that increasing concentrations of C3 resulted in a dose-dependent increase in cytotoxicity within a non-physiological range of 300 uM to 10 mM. Figure 2A and Figure 2B It was shown that increasing the concentration of C3 decreases the concentration of ATP. When the concentration of ATP decreases, the number of viable cells (and healthy cells) also decreases. After only 6 hours of exposure to C3, cytotoxicity was already observed at the highest concentration (10 mM). Fig. 8A ), and significant cytotoxicity was observed across the entire dose range (300uM to 10mM) in long-term evaluations ( Figure 8B ).

[0328] Therefore, it is concluded that under ketogenic diet-like treatment conditions, it is necessary to use low physiological concentrations of C3 (1 μM to 10 μM) to suppress maximal levels of ketone production from single fatty acids or fatty acid blends without compromising cellular health and viability.

[0329] 3.1 Effect of the combination of C4 and C6 on ketone production

[0330] The study found that when similar experiments were performed on these single ingredients, a combination of C4 and C6 at low physiological amounts (5 μM each) was used to treat the ketogenic diet (K-one) ( Fig.9A ) was enhanced in a non-additive manner. In the absence of a ketogenic fat blend, providing C4 or C6 alone or in combination produced almost no ketones, but when the combination of C4 and C6 was added to the fat blend, ketone production from the fat blend increased by about 40%. The observed increase was higher than would be predicted based on the effects of C4 and C6 on ketone production alone ( Fig.9A The 3rd and 4th bars are compared to the 6th bar, respectively). The dotted line represents the threshold of ketone production induced by the ketogenic fat blend. Fig. 9B The synergistic effect between the ketogenic fat blend and the combination of C4 and C6 is shown; the middle bar shows the expected effect on ketone production by adding the observed effects of C4 and C6 on ketone production individually, and the third bar on the right shows the actual synergistic effect observed for the co-incubation of C4 and C6. In summary, C4 and C6 together synergistically promote the highest level of ketone production of the ketogenic fat blend.

[0331] 3.2 Effects of the combination of C4, C6, citrate, and NR or NAM on ketone production

[0332] In the next assay, the potentiating or reinforcing effects of 5 μM C4, 5 μM C6, 200 μM citrate with 10 μM NR or 10 μM NAM were evaluated.

[0333] The experimental setup was similar to that of the single component experiments described above, except that the medium used in the starvation phase was modified:

[0334] At the end of the growth phase, the cells formed a monolayer and the medium was changed to DMEM containing 1 mM glucose and antibiotics (1% penicillin and streptomycin) but without FBS. The medium was further supplemented with L-carnitine (a cofactor required for the uptake of fatty acids by mitochondria, where they are converted to ketones). In order to specifically evaluate the effects of NR or NAM in the combination of various components, the medium was also depleted of vitamin B3 and tryptophan, since tryptophan can compensate for the lack of B3 (NAD+ precursor).

[0335] At the end of the starvation period, the medium was changed to Krebs-Henseleit buffer (KHB) supplemented with L-carnitine and the test nutrients used were as follows:

[0336] i) Complete combination of C4, C6, citrate and NR

[0337] ii) Complete combination of C4, C6, citrate and NAM

[0338] iii) Ketogenic Fat Blend

[0339] iv) Complete combination of C4, C6, Citrate and NR with ketogenic fat blend

[0340] v) Complete combination of C4, C6, Citrate and NAM with ketogenic fat blend

[0341] The production of βHB was then evaluated as described above. It was found that in the absence of a ketogenic fat blend, neither the combination with NR nor the combination with NAM produced significant amounts of ketones ( Fig.10). The use of the ketogenic fat blend alone results in ketone production, which is reflected by the dotted line in the figure and is referred to herein as the threshold level for ketone production. The combination with NR or the combination with NAM is further added to the ketogenic fat blend, resulting in a significant increase in ketone production, exceeding the threshold level. Unexpectedly, in both combinations, the increase above the threshold level brought about by either combination is greater than the ketone production achieved by either combination alone in the absence of the ketogenic fat blend. Therefore, the results demonstrate that the combination with NR and the combination with NAM have a non-additive synergistic effect on the ketone production of the ketogenic fat blend. Therefore, it was found that the combination of C4, C6, citrate with NR or NAM can enhance the highest level of ketone production in the ketogenic fat blend.

[0342] 4. Evaluation of dietary fiber fermentation

[0343] The fermentation of dietary fiber was evaluated using a standard adult intestinal microbiota library. The library was established by donating feces from 6 healthy adult volunteers (Caucasians, aged 25-60 years old, no antibiotics used within 3 months before donation, self-assessed health status). Before starting fermentation with the test compound, the standardized adult feces library was incubated overnight (37 ° C; 300 rpm) in SIEM (standard ileal effluent medium) under anaerobic conditions to activate bacteria, see: Schuren F et al., The i-screen:AVersatile Preclinical Platform for Gut Microbiota Studies [i-screen: General preclinical platform for intestinal microbiota research]. J Prob Health. [Journal of Probiotics and Health] 7: 212, 2019.

[0344] Dietary fibers were tested at concentrations of 6-10 mg / ml, depending on their viscosity and / or fermentability. All fibers were tested in triplicate. The following conditions were used:

[0345] - Partially hydrolyzed guar gum (Benefibre and Optifibre) 6.6 mg / ml

[0346] -Inulin (Orafti HP) 10mg / ml

[0347] -GOS (Vivinal GOS) 6mg / ml

[0348] -Locust bean gum (LBG) 6mg / ml

[0349] -Soybean fiber (Fibrim) 10mg / ml

[0350] -Soybean fiber (Fuji) 10mg / ml

[0351] -Cellulose (Vitacel) 10mg / ml

[0352] - Yeast β-glucan (YBG) 10mg / ml

[0353] -Mixture A, containing GOS, inulin, soy fiber (Fuji), resistant starch (Novelose 330), 10 mg / ml

[0354] -Mixture B, containing FOS, inulin, soy fiber (Fibrim), resistant starch (Novelose 330), gum arabic, cellulose (Vitacel), 6.6 mg / ml

[0355] Each run included a negative control (blank control medium containing only that feces pool), and all conditions started at pH 6.3. After 24 h of anaerobic fermentation in SIEM medium at 37°C, samples were collected for pH measurement and metabolite analysis.

[0356] The pH values ​​were measured by immersing a 423 pH-electrode (Mettler Toledo, Columbus, OH, USA) connected to a Handy-lab pH meter (Schott Glas, Mainz, Germany) directly into the sample.

[0357] SCFA (covering acetate, propionate and n-butyrate) and branched chain fatty acids (BCFA) (covering isobutyrate and isovalerate) were analyzed according to the method described by Jouany et al. (1982) and modifications described by Van Nuenen et al. (2003). Briefly, the fermented material in the i-screen sample was centrifuged (about 12,000g, 5min). Cells were removed from the supernatant by sterile filtration (0.45μm). A mixture of formic acid (20%), methanol and 2-ethylbutyric acid (internal standard, 2mg / ml in methanol) was added. 3μl of the sample was injected into a GC column (ZB5HTinferno, ID 0.52mm, film thickness 0.10μm; Zebron; Phenomenex, USA) in a Shimadzu GC-2014 gas chromatograph at a split ratio of 75.0.

[0358] The results showed that after 24 h of fermentation, inulin, GOS, soy fiber, cellulose and the two mixtures obtained higher butyrate / propionate ratios (>1.2) compared with the blank control ( Fig.11). Dietary fibers having a butyrate to propionate ratio of at least 1 and mixtures of such fibers are considered to be butyrate-producing dietary fibers according to the present invention. In contrast, the butyrate / propionate ratios of partially hydrolyzed guar gum, LBG and YBG are still below 1.

[0359] 5. Impact of the first and second compositions

[0360] A non-limiting example of the use of the first and second compositions may be as follows: A 70 kg male subject who is about to start a ketogenic diet will be treated with the first and second compositions to control ketosis. The subject will consume a ketogenic diet of about 3000 kcal per day. Blood ketone levels are monitored daily using test strips. Before each meal, the subject will take the first composition. Thus, the subject will take the first composition comprising 7 mg butyric acid and 455 mg caproic acid three times daily. When the blood ketone level is determined to rise above 3 mmol / L using the test stick, one or more doses of the second composition comprising 6 mg propionic acid per dose will be administered to the subject.

[0361] Another non-limiting example of using the first and second compositions may be as follows: a 70 kg male subject who will start a ketogenic diet will be treated with the first and second compositions to control ketosis. The subject will consume a ketogenic diet of about 3000 kcal per day. Blood ketone levels are monitored daily using test strips. Before each meal, the subject will take the first composition. Thus, the subject will take a first composition comprising 14 mg butyrate, 910 mg caproate, 1.4 g citrate, and 84 mg NR and optionally 70 mg acetic acid three times daily. When the blood ketone level is determined to rise above 3 mmol / L using the test stick, one or more doses of the second composition comprising 12 mg propionic acid per dose will be administered to the subject.

Claims

1. A first composition providing at least one of butyric acid or caproic acid and optionally acetic acid, the composition being used for Controlling ketosis associated with a ketogenic diet in a subject following a ketogenic diet, wherein at least one of butyric acid or caproic acid and optionally acetic acid is contained in a non-ketogenic amount in the first composition, or at least one of butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyric acid dietary fiber or a butyric acid dietary fiber blend contained in the first composition, wherein the therapeutic use relates to a) administering the first composition to the subject, c) Optionally, administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid if the blood ketone level is above 3 mmol / L.

2. The first composition for use according to claim 1, wherein the therapeutic use further involves b) measuring blood ketone and / or urine ketone levels.

3. A first composition for use according to claims 1 and 2, wherein the first and second compositions are used sequentially, optionally more than once sequentially.

4. The first composition for use according to any one of the preceding claims, wherein the subject following a ketogenic diet suffers from a condition selected from the group consisting of: i) Neurological diseases, including epilepsy, stroke, traumatic brain injury, and migraine; ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and age-related mild cognitive impairment (MCI); iii) neuromuscular disease, including amyotrophic lateral sclerosis, muscle deactivation, muscle atrophy and sarcopenia caused by aging, or risk of or frailty in old age; iv) psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder; v) metabolic disorders, including insulin resistance, type 1 and type 2 diabetes, glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases; vi) tumor diseases; vii) Cardiovascular disease leading to heart failure.

5. The first composition for use according to any one of the preceding claims, wherein the first composition further comprises one or more compounds selected from citrate, nicotinamide riboside and nicotinamide.

6. A first composition for use according to any one of the preceding claims, wherein the first composition comprises (i) Butyric acid (ii) Hexanoic acid (iii) Citrate and (iv) Nicotinamide riboside or nicotinamide.

7. The first composition for use according to any one of the preceding claims, wherein the first composition is administered at the following dosage: (i) 0.2 to 12 mg butyrate per kg body weight per day (ii) 6 to 165 mg of caproic acid per kg body weight per day (iii) 0.01 g to 0.4 g citrate per kg body weight per day, and (iv) 0.5 mg to 15 mg of nicotinamide riboside per kg body weight per day.

8. The first composition for use according to any one of the preceding claims, wherein the first composition enhances ketosis in a subject following a ketogenic diet.

9. A first composition for use according to any one of the preceding claims, wherein the second composition (i) reduce ketone production and / or (ii) prevention and / or treatment of ketoacidosis, Wherein (i) reducing ketone production and / or (ii) preventing and / or treating ketoacidosis comprises reducing blood ketone levels to below 3 mM.

10. Propionic acid for use in the treatment of: in a subject following a ketogenic diet and using a first composition providing at least one of butyrate or caproate and optionally acetic acid i) Control the effects of a ketogenic diet and / or ii) Control of ketone body production, Wherein at least one of the butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition.

11. Propionic acid for therapeutic use according to claim 10, wherein i) controlling the effects of a ketogenic diet and / or ii) controlling ketone body production involves lowering blood ketone bodies to within the range of 1.0 to 3.0 mmol / L.

12. Propionic acid for therapeutic use according to claims 10 and 11, wherein the therapeutic use relates to a) applying the first composition, b) administering a second composition comprising propionic acid to reduce ketone production / administering a second composition comprising propionic acid.

13. Propionic acid for therapeutic use according to claim 12, wherein the therapeutic use further involves c) measuring blood ketone and / or urine ketone levels.

14. A set box, the set box comprising: 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1; 2) a first composition comprising at least one of butyric acid or caproic acid and optionally acetic acid, wherein the at least one of butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the at least one of butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition; 3) A second composition comprising propionic acid.

15. A kit for use in: (i) controlling and / or regulating ketosis and / or (ii) controlling and / or regulating ketone body production associated with a ketogenic diet in a subject following a ketogenic diet, the kit comprising: 1) a ketogenic dietary composition having a ketone weight ratio between 1:1 and 4:1; 2) providing a first composition of at least one of butyric acid or caproic acid and optionally acetic acid, wherein the at least one of butyric acid or caproic acid and optionally acetic acid is contained in the first composition in a non-ketogenic amount, or the at least one of butyric acid or caproic acid and optionally acetic acid is provided in a non-ketogenic amount by a butyrate-producing dietary fiber or a butyrate-producing dietary fiber blend contained in the first composition; 3) A second composition comprising propionic acid.